JP2006501240A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501240A5
JP2006501240A5 JP2004531017A JP2004531017A JP2006501240A5 JP 2006501240 A5 JP2006501240 A5 JP 2006501240A5 JP 2004531017 A JP2004531017 A JP 2004531017A JP 2004531017 A JP2004531017 A JP 2004531017A JP 2006501240 A5 JP2006501240 A5 JP 2006501240A5
Authority
JP
Japan
Prior art keywords
formulation
injection
site
unacceptable
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004531017A
Other languages
English (en)
Japanese (ja)
Other versions
JP4729306B2 (ja
JP2006501240A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/025573 external-priority patent/WO2004017897A2/en
Publication of JP2006501240A publication Critical patent/JP2006501240A/ja
Publication of JP2006501240A5 publication Critical patent/JP2006501240A5/ja
Application granted granted Critical
Publication of JP4729306B2 publication Critical patent/JP4729306B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004531017A 2002-08-20 2003-08-14 アリピプラゾール錯体の製剤と方法 Expired - Fee Related JP4729306B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40471302P 2002-08-20 2002-08-20
US60/404,713 2002-08-20
PCT/US2003/025573 WO2004017897A2 (en) 2002-08-20 2003-08-14 Aripiprazole complex formulation and method

Publications (3)

Publication Number Publication Date
JP2006501240A JP2006501240A (ja) 2006-01-12
JP2006501240A5 true JP2006501240A5 (https=) 2006-06-08
JP4729306B2 JP4729306B2 (ja) 2011-07-20

Family

ID=31946748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004531017A Expired - Fee Related JP4729306B2 (ja) 2002-08-20 2003-08-14 アリピプラゾール錯体の製剤と方法

Country Status (32)

Country Link
US (8) US7115587B2 (https=)
EP (1) EP1542668B1 (https=)
JP (1) JP4729306B2 (https=)
KR (1) KR101043866B1 (https=)
CN (1) CN100335047C (https=)
AR (2) AR040887A1 (https=)
AT (1) ATE428423T1 (https=)
AU (1) AU2003269965B2 (https=)
BR (1) BR0313602A (https=)
CA (1) CA2495864C (https=)
CY (1) CY1110331T1 (https=)
DE (1) DE60327225D1 (https=)
DK (1) DK1542668T3 (https=)
ES (1) ES2322953T3 (https=)
GE (1) GEP20063996B (https=)
HR (1) HRP20050149B1 (https=)
IL (1) IL166623A (https=)
IS (1) IS2878B (https=)
MX (1) MXPA05001865A (https=)
MY (1) MY140793A (https=)
NO (1) NO333458B1 (https=)
NZ (1) NZ537995A (https=)
PE (1) PE20040895A1 (https=)
PL (1) PL212428B1 (https=)
PT (1) PT1542668E (https=)
RS (1) RS51903B (https=)
RU (1) RU2342931C2 (https=)
SI (1) SI1542668T1 (https=)
TW (1) TWI307626B (https=)
UA (1) UA79984C2 (https=)
WO (1) WO2004017897A2 (https=)
ZA (1) ZA200501064B (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170705A1 (en) * 2001-03-08 2004-09-02 Dusan Miljkovic Compositions and methods for non-insulin glucose uptake
ATE428423T1 (de) 2002-08-20 2009-05-15 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
UA82561C2 (uk) * 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
ES2374922T3 (es) * 2003-12-16 2012-02-23 Teva Pharmaceutical Industries Ltd. Procedimientos de preparación de formas cristalinas de aripiprazol.
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
ES2326354B1 (es) * 2005-04-13 2010-07-08 Elan Pharma International Limited Composiciones de liberacion controlada y nanoparticuladas que comprenden derivados de prostaglandina.
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
CA2611917A1 (en) * 2005-06-13 2006-12-21 Takeda Pharmaceutical Company Limited Injection
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US7858609B2 (en) 2005-11-28 2010-12-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
CN101322709B (zh) * 2007-06-12 2011-03-02 成都康弘药业集团股份有限公司 一种含有阿立哌唑的药物组合物及其制备方法
SI2170279T1 (en) * 2007-07-31 2018-04-30 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
WO2009048947A1 (en) * 2007-10-09 2009-04-16 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors
AU2009225719A1 (en) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2937222C (en) * 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
KR101125210B1 (ko) * 2009-09-11 2012-03-19 주식회사 대웅제약 아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
US20110140304A1 (en) * 2009-12-10 2011-06-16 Molecular Imprints, Inc. Imprint lithography template
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
HUE065359T2 (hu) 2011-03-18 2024-05-28 Alkermes Pharma Ireland Ltd Szorbitán-észtereket tartalmazó gyógyászati készítmények
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
WO2013123254A1 (en) 2012-02-15 2013-08-22 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
ES2765036T3 (es) 2012-03-19 2020-06-05 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden esteres de ácidos grasos
ES2950418T3 (es) 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
EP2897592B1 (en) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
GR1008186B (el) 2013-04-22 2014-05-08 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150086408A1 (en) * 2013-09-26 2015-03-26 General Electric Company Method of manufacturing a component and thermal management process
HRP20220112T1 (hr) 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
GR1008442B (el) 2014-01-16 2015-03-05 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
BR112016021535A8 (pt) 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
CN105078910B (zh) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 一种含有依匹哌唑的冻干口服制剂及其制备方法
AU2016338672A1 (en) 2015-10-16 2018-04-12 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
CN105616344A (zh) * 2016-01-06 2016-06-01 万全万特制药江苏有限公司 阿立哌唑注射液及其制备方法
EP3494125B1 (en) * 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN110022857A (zh) 2016-11-18 2019-07-16 艾库里斯抗感染治疗有限公司 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
US11033506B2 (en) * 2017-11-21 2021-06-15 Sekisui Chemical Co., Ltd. External skin preparation comprising a core-shell structure
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
JP7754799B2 (ja) 2019-08-05 2025-10-15 マリナス ファーマシューティカルズ， インコーポレイテッド てんかん重積状態の治療に使用するためのガナキソロン
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
JP2023551145A (ja) * 2020-11-18 2023-12-07 ベクソン バイオメディカル，インク． 医薬化合物の錯化剤塩製剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2893175B2 (ja) * 1988-10-31 1999-05-17 大塚製薬株式会社 カルボスチリル誘導体
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US5646131A (en) 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
JPH10194996A (ja) 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
ATE428423T1 (de) * 2002-08-20 2009-05-15 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
CN1703198A (zh) 2002-10-25 2005-11-30 辉瑞产品公司 呈混悬剂形式的芳基杂环活性物质的贮库制剂

Similar Documents

Publication Publication Date Title
JP2006501240A5 (https=)
EA200600820A1 (ru) Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
JP2005520778A5 (https=)
NO20014519D0 (no) Apomorfin- og sildenafilpreparat
JP2013522303A5 (https=)
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
JP2005524663A5 (https=)
JP2005537234A5 (https=)
JP2015524444A5 (https=)
PL2043637T3 (pl) Sposoby i leki do podawania ibuprofenu
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
DE60235178D1 (de) Darreichungsformen mit verlängerter wirkstofffreisetzung
FI3840753T3 (fi) Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio
JP2018526460A5 (https=)
JP2013518124A5 (https=)
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
ATE546136T1 (de) Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln
EP2424536A4 (en) NEW PHOTOSENSIBILIZER FORMULATIONS FOR ORAL ADMINISTRATION
RU2010146309A (ru) Фармацевтическая композиция для лечения фибромиалгии
GEP201606538B (en) Preoperative treatment of post operative pain
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
RU2004105675A (ru) Способ комплексного лечения язв роговицы
WO2008079818A3 (en) Intravenous administration of water soluble analgesic formulations
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease